Itopride Treatment Protocol for Functional Dyspepsia and GERD

Clinical Positioning and Efficacy

The American Gastroenterological Association recommends itopride as first-line therapy for dysmotility-like symptoms, including postprandial fullness, early satiety, bloating, and upper abdominal discomfort, with a strength of evidence rated as moderate 1, 2
Itopride can be prescribed after H. pylori eradication in patients with persistent dysmotility symptoms, with a strength of evidence rated as low 1
The European Society of Gastrointestinal Motility suggests itopride as effective add-on therapy to PPIs in patients with inadequate response to PPI monotherapy, with a strength of evidence rated as moderate 2
Available prokinetics in Asia, including itopride, mosapride, and domperidone, have a modest overall effect, with a strength of evidence rated as low 2

The American College of Gastroenterology states that itopride has an excellent safety profile, with adverse event rates of only 1.5-3.1% in clinical studies, and no cardiac toxicity or QT prolongation has been reported, with a strength of evidence rated as high 1
The European Society of Gastroenterology recommends itopride as first-line for dysmotility-predominant functional dyspepsia, with symptoms of fullness, bloating, early satiety, with a strength of evidence rated as moderate 1, 2
The American Gastroenterological Association suggests itopride as add-on therapy for PPI-refractory GERD, when acid suppression alone is insufficient, with a strength of evidence rated as moderate 2

The quality of evidence for prokinetics in general is rated as low, with weak recommendations by major gastroenterology societies, including the American College of Gastroenterology and the European Society of Gastroenterology, with a strength of evidence rated as low 3
The European Society of Gastrointestinal Motility notes that prokinetics have a modest overall effect in GERD, with a systematic review showing no benefit of mosapride plus PPI versus PPI monotherapy, though itopride may perform differently, with a strength of evidence rated as low 2

Itopride enhances acetylcholine release and improves gastrointestinal motility without the cardiac risks that are associated with cisapride or tegaserod, indicating a safer pro‑kinetic profile【4】.

Compared with metoclopramide, itopride does not carry a significant risk of extrapyramidal side effects or irreversible tardive dyskinesia, making it safer for patients prone to movement disorders【4】.
Unlike domperidone, long‑term use of itopride does not require routine QTc interval monitoring, reflecting a lower potential for cardiac arrhythmia【4】.

The absence of cardiac toxicity with itopride differentiates it from cisapride (withdrawn because of fatal arrhythmias) and tegaserod (withdrawn due to cardiovascular events), supporting its use when cardiac safety is a concern【4】.

Metoclopramide remains effective for dysmotility but is associated with a notable risk of extrapyramidal side effects and tardive dyskinesia, especially in older adults, limiting its long‑term suitability【4】.

Tricyclic antidepressants (e.g., low‑dose amitriptyline) are recommended as second‑line agents for functional dyspepsia when symptoms are more acid‑predominant, providing a neuromodulatory approach【5】.

Prucalopride, a selective 5‑HT₄ receptor agonist, has shown promise for constipation‑predominant dyspepsia and does not affect the QT interval, offering a cardiac‑safe alternative【4】.